VAGINAL FUNGI INFECTIONS TREATMENT MARKET ANALYSIS

Vaginal fungi infections is identified by various symptoms such as swelling around the vagina, burning sensation during urination or sex, whitish-gray and clumpy vaginal discharge, and many others. Vaginal yeast infection is also known as candidiasis. A healthy vagina comprises bacteria and few yeast cells, but when the balance of bacteria and yeast changes, the yeast cells can multiply, which further leads to intense itching, swelling, and irritation.

The global vaginal fungi infections treatment market is estimated to be valued at US$ 987.2 million in 2020 and is expected to exhibit a CAGR of 5.3% during the forecast period (2020-2027).

Figure 1. Global Vaginal Fungi Infections Treatment Market Share (US$ Mn), by Region, 2020

To learn more about this report, request sample copy

The increasing product launches is expected to propel growth of the global vaginal fungi infections treatment market

Major players in the market are focused on product launches in the market, which is expected to boost the market growth over the forecast period. For instance, in December 2016, Dr. Reddy’s Laboratories Ltd. launched Nystatin and Triamcinolone Acetonide Cream, USP, approved by the U.S. Food & Drug Administration (U.S. FDA).in the U.S. Nystatin and Triamcinolone Acetonide Cream, USP are the generic equivalent of Nystatin and Triamcinolone Acetonide Cream, USP 100,000 units/g- 0.1% manufactured by Taro Pharmaceuticals USA Inc. and these are used to treat fungal or yeast infections of the skin.

Moreover, increasing inorganics strategies such as business expansion adopted by the market players are expected to propel growth of the global vaginal fungi infections treatment market during the forecast period. For instance, in June 2016, Bausch Health Companies Inc. (previously known as Valeant Pharmaceuticals International, Inc.) announced that its subsidiary Valeant Canada is expanding its manufacturing and export capacity in Canada.

However, alternative therapies for vaginal fungi infections treatment can hinder the market growth. For instance, Pure Essence, a dietary supplement company offers Candex, a mixture of potent enzymes, which break down the substances that make up the cell walls of Candida yeast.

Figure 2. Global Vaginal Fungi Infections Treatment Market Share (%), by Drug Type, 2020

To learn more about this report, request sample copy

Increasing opioid abuse in North America is expected to boost the market growth

North America is expected to hold dominant position in the global vaginal fungi infections treatment market, owing to burden of recurrent vulvovaginal candidiasis in this region. For instance, according to The Lancet, an article published in August 2018, reports that in the U.S. there were 3,775 and 3,897 base case prevalence per 100,000 females in the U.S. and Canada respectively.

Moreover, increasing acquisitions by key players in the region is expected to drive the market growth during the forecast period. For instance, in February 2019, Aurobindo Pharma Limited acquired commercial operations and certain supporting infrastructure of Apotex Inc. in five European countries.

Global Vaginal Fungi Infections Treatment Market – Impact of Coronavirus (COVID-19) Pandemic

The coronavirus (COVID-19) pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare is one such sector which has been impacted significantly by the COVID-19 pandemic.

The lockdown in various countries due to the pandemic has placed an economic burden on the healthcare sector. Moreover, the coronavirus pandemic has hampered the development, production, and supply of drugs and other healthcare products and affected growth of healthcare businesses of various companies across the globe.

As a result, the impact of the COVID-19 pandemic is also expected to limit growth of the global vaginal fungi infections treatment drugs market during the forecast period.

However, the COVID-19 pandemic is also expected to limit growth of the global vaginal fungi infections treatment market during the forecast period. According to the Journal of Clinical Orthopedics and trauma, in May 2020, the coronavirus affects bones and joints of affected patients. As a result, several orthopedic doctors have been deployed for monitoring patients suffering from coronavirus infection. In order to treat such patients, there has been an increase in the manufacture of drugs and research and development.

Key Players

Major players operating in the global vaginal fungi infections treatment market include Pfizer Inc., Bausch Health Companies Inc, ANI Pharmaceuticals, Inc., Hikma Pharmaceuticals Plc, Lupin Limited, Mycovia Pharmaceuticals, Inc., Glenmark Pharmaceuticals Limited, Unique Pharmaceuticals, PEPTONIC medical AB, Aurobindo Pharma Limited, Dr. Reddy's Laboratories, and SCYNEXIS, Inc.